Suggested remit: To appraise the clinical and cost effectiveness of durvalumab with tremelimumab within its marketing authorisation for untreated advanced or unresectable hepatocellular carcinoma in adults.
Status In progress
Technology type Medicine
Decision Selected
Process STA Standard
ID number 2725

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
08 April 2024 - 06 May 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 2725
28 March 2024 In progress. Please note that following on from advice received from the company this topic has now been scheduled back into the work programme. We now anticipate that the appraisal will begin during mid-June 2024 when we will write to you about how you can get involved.
22 November 2023 Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal at this time. Therefore, we are suspending the appraisal while we consider the next steps.
10 January 2020 In progress. Referred October 28 2019

For further information on our processes and methods, please see our CHTE processes and methods manual